Journal of Pharmacokinetics and Pharmacodynamics

Papers
(The H4-Index of Journal of Pharmacokinetics and Pharmacodynamics is 13. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-08-01 to 2025-08-01.)
ArticleCitations
Application of different approaches to generate virtual patient populations for the quantitative systems pharmacology model of erythropoiesis48
Population pharmacokinetic and pharmacodynamic model of propofol externally validated in Korean elderly subjects47
Translational physiologically-based pharmacokinetic model for ocular disposition of monoclonal antibodies33
Development of PBPK model for intra-articular injection in human: methotrexate solution and rheumatoid arthritis case study27
Advancing inclusive healthcare through PBPK modelling: predicting the impact of CYP genotypes and enzyme ontogenies on infant exposures of venlafaxine and its active metabolite O-desmethylvenlafaxine 22
Learning pharmacometric covariate model structures with symbolic regression networks21
Achieving big with small: quantitative clinical pharmacology tools for drug development in pediatric rare diseases16
Convolution-based approach for modeling the paliperidone extended release and Long-Acting Injectable (LAI) PK of once-, and three-monthly products administration and for optimizing the development of 16
Model-informed approach to estimate treatment effect in placebo-controlled clinical trials using an artificial intelligence-based propensity weighting methodology to account for non-specific responses15
Characterization of exposure–Clinical Dementia Rating–Sum of Boxes relationship in subjects with early Alzheimer’s disease from the aducanumab Phase 3 trials14
Semi-mechanistic modeling of resistance development to β-lactam and β-lactamase-inhibitor combinations14
Correction: Model-based comparison of subcutaneous versus sublingual apomorphine administration in the treatment of motor fluctuations in Parkinson’s disease13
Translational population target binding model for the anti-FcRn fragment antibody efgartigimod13
Mixed effect estimation in deep compartment models: Variational methods outperform first-order approximations13
0.048259019851685